Signaling Pathway News and Research

RSS

Mutated RIG-I receptor causes kidney inflammation through Y-RNA activation

Researchers at the University Hospital Bonn (UKB) and the University of Bonn have discovered how a small, naturally occurring RNA molecule in the kidney activates a mutated immune receptor, triggering a chain reaction.

31 Oct 2025

Thiostrepton suppresses rhabdomyosarcoma progression by targeting the PI3K–AKT pathway

Rhabdomyosarcoma (RMS) accounts for up to 10% of childhood cancers and nearly half of pediatric soft tissue sarcomas.

30 Oct 2025

Specialized type of cardiac fibroblasts can actively worsen heart failure

Heart failure (HF) is one of the leading causes of death and disability worldwide, affecting millions of people and placing an enormous burden on healthcare systems.

29 Oct 2025

Study finds evidence for repurposing thiostrepton as an anti-rhabdomyosarcoma drug

Rhabdomyosarcoma (RMS) accounts for up to 10% of childhood cancers and nearly half of pediatric soft tissue sarcomas.

27 Oct 2025

Researchers uncover and inhibit a key cell death pathway in severe cutaneous adverse reactions

A collaborative research group led by Haruna Kimura (graduate student), Dr. Akito Hasegawa (Assistant Professor), and Prof. Riichiro Abe from the Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, together with Prof. Takemasa Ozawa from the Department of Chemistry, School of Science, The University of Tokyo, and Dr. Yoichi Ogawa (Lecturer) from the Department of Dermatology, Faculty of Medicine, University of Yamanashi, has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous adverse reactions such as Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

24 Oct 2025

$VT3989 shows promising antitumor activity in refractory mesothelioma patients$

VT3989 shows promising antitumor activity in refractory mesothelioma patients

The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to results from a trial led by researchers from The University of Texas MD Anderson Cancer Center.

22 Oct 2025

Immune checkpoint inhibitor TIGIT found to promote tissue healing

Immune checkpoint inhibitors are well known as a form of cancer treatment. Researchers at UZH have now identified a new, important function of these inhibitors: promotion of tissue healing.

15 Oct 2025

Combination therapy shows promising results in patients with rare subtype of non-Hodgkin lymphoma

Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body's natural response to viral infections, showed promising results in patients with relapsed or refractory natural killer/T-cell lymphoma (R/R NKTL), a rare and aggressive cancer with limited treatment options.

15 Oct 2025

Discovery of CPD gene mutations sheds light on rare congenital hearing loss

Mutations in a gene known as CPD play a crucial role in a rare form of congenital hearing loss, an international team of researchers has discovered.

14 Oct 2025

Decoding the signaling networks and metabolic dysregulation underlying sepsis

Sepsis is a complex clinical syndrome characterized by dysregulated immune responses, systemic inflammation, and multi-organ dysfunction.

10 Oct 2025

Study reveals how DKK3 triggers smooth muscle cell transformation in aortic aneurysm

Abdominal aortic aneurysm (AAA) is a life-threatening vascular disorder that primarily affects elderly males.

10 Oct 2025

Study reveals acidic conditions as key to pancreatic cancer survival

Tumors are not a comfortable place to live: oxygen deficiency, nutrient scarcity, and the accumulation of sometimes harmful metabolic products constantly stress cancer cells.

9 Oct 2025

Decades of exercise found to train the immune system for better defense

In addition to strengthening the muscles, lungs, and heart, regular physical exercise also strengthens the immune system.

8 Oct 2025

Innovative approaches target PAR2 receptor to alleviate gut pain

Abdominal pain is a hallmark of many digestive disorders, including inflammatory bowel disease and irritable bowel syndrome.

7 Oct 2025

Gut probiotic Christensenella tenuis reduces endotoxemia and improves metabolism in obese mice

This study is reported by the team of Professor Shuang-jiang Liu from Shandong University. The study reveals that the gut probiotic Christensenella tenuis significantly alleviates endotoxemia and metabolic disorders in a diet-induced obesity (DIO) mouse model by modulating gut bile acids (BAs) metabolism and suppressing lipopolysaccharide (LPS) translocation across the gut barrier.

26 Sep 2025

Targeting TGF-β signaling as a strategy to treat liver fibrosis

Liver fibrosis, a pathological scarring process resulting from chronic liver injury, represents a significant global health burden due to its potential progression to cirrhosis and hepatocellular carcinoma.

25 Sep 2025

How food choices and cooking methods drive brain inflammation and disease

Researchers reviewing evidence in NeuroSci show how dietary AGEs and their interaction with RAGE drive oxidative stress, inflammation, and neurodegeneration. They highlight how cooking methods and diet choices could lower AGE burden and protect brain health, while calling for rigorous clinical trials.

24 Sep 2025

GPR120 plays a key role in mediating the effects of n-3 fatty acids on mammary function

During lactation, the mammary gland undergoes significant structural and functional changes to produce milk, which is essential for neonatal nutrition and early immune development.

23 Sep 2025

Metabolic activity found to control the tempo of embryo segmentation clock

Pregnant women rely on a balanced diet and supplements to deliver proper nutrients to their babies, to ensure they grow healthfully.

19 Sep 2025

Low dose of aspirin cuts recurrence risk in colorectal cancer with genetic mutation

A Swedish-led research team at Karolinska Institutet and Karolinska University Hospital has shown in a new randomized clinical trial that a low dose of the well-known medicine aspirin halves the risk of recurrence after surgery in patients with colon and rectal cancer with a certain type of genetic alteration in the tumor.

17 Sep 2025